Back

Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval - discussion

31 August 2026 (15:00 - 15:15)
Organised by: Logo
Congress Presentation Part of: Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

3 More presentations in this session

Presentation thumbnail
Artificial intelligence-enabled target discovery: decoding cardiometabolic pathways from omics to mechanism
Doctor M. Kelm (Berlin, DE)
Slides Video
Presentation thumbnail
Digital trials: how artificial intelligence optimises phenotyping, recruitment, and adaptive designs in cardiometabolic therapeutics
Doctor S. Niederer (London, GB)
Slides Video
Presentation thumbnail
Regulatory science meets artificial intelligence: pathways for approval of artificial intelligence-developed cardiometabolic drugs
Professor P. Szymanski (Warszawa, PL)
Slides Video

Access the full session

Session thumbnail
Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 15:00 CET
You may be interested in
thumbnail
Congress Presentation
AI-based drug design and AI-based clinical trials - discussion
22 November 2025
thumbnail
Congress Presentation
The new toolbox for cardiovascular discovery: from multiomics to computational modelling - discussion
28 August 2026
thumbnail
Congress Presentation
Using artificial intelligence to select therapeutic targets in early phase trials
30 August 2026
thumbnail
Congress Presentation
Beyond biomarkers: artificial intelligence-driven insights into cardiometabolic disease - discussion
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources